Scientific Reports (Sep 2022)

Hepcidin discriminates sepsis from other critical illness at admission to intensive care

  • Jon Olinder,
  • Alex Börjesson,
  • Jakob Norrman,
  • Tobias West,
  • Joakim Carlström,
  • Alexander Gustafsson,
  • Martin Annborn,
  • Heiko Herwald,
  • Cecilia Rydén

DOI
https://doi.org/10.1038/s41598-022-18826-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Initial differential diagnosis and prognosis for patients admitted to intensive care with suspected sepsis remain arduous. Hepcidin has emerged as a potential biomarker for sepsis. Here we report data on the relevance of levels of hepcidin versus other biomarkers as a diagnostic and prognostic tool for sepsis. 164 adult patients admitted to the intensive care unit (ICU) within 24 h upon arrival to the hospital were included. Blood samples collected daily for seven consecutive days and hepcidin levels, heparin binding protein (HBP) levels and standard biomarkers were determined. Blood cultures were initiated at inclusion. Clinical scores were evaluated daily and mortality after 28- and 180-days was recorded. One hundred of the patients were found to fulfil the criteria for sepsis whereas 64 did not. Hepcidin levels at admission were significantly higher in the septic than in the non-septic patients. In septic patients hepcidin levels declined significantly already at 24 h followed by a steady decline. A significant negative correlation was observed between hepcidin levels and SAPS 3 in patients with sepsis. Hepcidin levels at inclusion were significantly higher among septic patients that survived 180-days and predicted mortality. Our data show that hepcidin levels are indicative of sepsis in patients admitted to the ICU and has a prognostic value for mortality.